hero image

Biogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009

January 9, 2009 Investor Relations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and full year 2008 financial results on Friday, February 6, 2009 before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:30 am ET. To access the live webcast, please go to Biogen Idec’s website at http://investor.biogenidec.com/. Following the live webcast, an archived version of the call will be available at the same URL, for one month.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

 

Contact:

Biogen Idec
Rob Jacobson, 877-420-2442

thumb
May 14, 2021
Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends in several prespecified secondary endpoints, such as a clinically relevant measure of visual acuity Biogen will communicate next steps for the program after analyzing the complete data set Currently

thumb
May 13, 2021
Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

As part of the agreement, Biogen will leverage Envisagenics’ AI platform with the goal of better understanding Central Nervous System diseases CAMBRIDGE, Mass. and NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance